Hengrui Pharmaceuticals Posts Double-Digit Profit Growth in Strong Q1 2026

An announcement from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.

Jiangsu Hengrui Pharmaceuticals reported solid year-on-year growth for the first quarter of 2026, with operating revenue rising 13% to RMB 8.14 billion and net profit attributable to shareholders climbing nearly 22% to RMB 2.28 billion. The company’s total assets reached RMB 71.29 billion and equity attributable to owners increased almost 4%, underlining its expanding financial strength.

Core profitability also improved, as net profit excluding non-recurring items advanced about 17% and basic and diluted earnings per share grew to RMB 0.34, while operating cash flow surged more than 40%. These results indicate robust demand for Hengrui’s products, stronger cash generation, and a slight uptick in return on net assets, reinforcing its competitive position in China’s pharmaceutical industry and offering reassurance to investors about its current operational momentum.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$92.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading Chinese pharmaceutical company focused on the research, development, manufacturing, and sales of innovative and generic medicines. Listed in Hong Kong as a Class H share issuer, it serves both domestic and international markets with a portfolio spanning oncology, anesthesia, and other therapeutic areas, positioning it as a major player in China’s healthcare sector.

Average Trading Volume: 3,295,311

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$427.6B

Find detailed analytics on 1276 stock on TipRanks’ Stock Analysis page.